Key result
Braile Inovare transcatheter aortic valve-in-valve implantation shows feasibility with 0% operative mortality in high-risk patients.
Why the study?
Aortic valve replacement for bioprosthesis dysfunction involves considerable risk and high mortality, making minimally invasive transcatheter valve-in-valve implantation a potential alternative to reduce morbidity and mortality.
Is transcatheter aortic valve-in-valve implantation using the Braile Inovare prosthesis safe and effective in patients with aortic bioprosthesis dysfunction?
Observational (n=14)
Is transcatheter aortic valve-in-valve implantation using the Braile Inovare prosthesis safe and effective in patients with aortic bioprosthesis dysfunction?
Transcatheter aortic valve-in-valve implantation using the Braile Inovare prosthesis is a feasible and safe alternative for high-risk patients with aortic bioprosthesis dysfunction.
No takes yet. Share an insight, caveat, or question.
May offer alternative for high-risk bioprosthesis dysfunction; leaves open need for larger trials on safety and durability.
Gaia et al. (2012) conducted an observational in double aortic bioprosthesis dysfunction (n=14). Transcatheter aortic valve-in-valve implantation using Braile Inovare prosthesis was evaluated on 30-day mortality. Transcatheter aortic valve-in-valve implantation using the Braile Inovare prosthesis was safe and feasible in 14 high-risk patients, with 0% operative mortality and 14.3% 30-day mortality.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: